Literature DB >> 17134631

Comparison of apolipoprotein-B/apolipoprotein-AI in subjects with versus without the metabolic syndrome.

Justo Sierra-Johnson1, Virend Kristen Somers, Fatima Helena Sert Kuniyoshi, Carolina Ana Garza, William Luther Isley, Apoor Suresh Gami, Francisco Lopez-Jimenez.   

Abstract

Recent studies have suggested that the apolipoprotein-B (apo-B)/apolipoprotein-AI (apo-AI) ratio predicts cardiovascular risk better than any of the cholesterol indexes. The aim of the present study was to assess if the apo-B/apo-AI ratio is related to the metabolic syndrome and its components. Data were analyzed from 2,964 subjects (mean age 48 years; 1,516 men, 1,448 women) from the National Health and Nutrition Examination Survey III with apolipoprotein data who were evaluated for the metabolic syndrome and its components. The metabolic syndrome was defined according to the criteria of the National Cholesterol Education Program Adult Treatment Panel III and the International Diabetes Federation. The mean values of the apo-B/apo-AI ratio in subjects with and without the metabolic syndrome were compared. Overall, the median distribution of the apo-B/apo-AI ratio was significantly greater (p <0.0001) in subjects with the Adult Treatment Panel III metabolic syndrome (0.90) than without (0.69). The apo-B/apo-AI ratio was associated significantly with each of the metabolic syndrome components, in descending order of magnitude: low high-density lipoprotein cholesterol (odds ratio [OR] 5.7), high triglycerides (OR 4.7), high waist circumference (OR 2.6), high fasting glucose (OR 1.9), and high blood pressure (OR 1.5). The apo-B/apo-AI ratio was also different between subjects with and without the metabolic syndrome. Mean values of apo-B/apo-AI increased significantly as the numbers of metabolic syndrome components increased in men (p <0.0001) and women (p <0.0001). After excluding high-density lipoprotein cholesterol and triglycerides as criteria for the metabolic syndrome, the association between means persisted (analysis of variance p <0.0001) in men and women. Apo-B/apo-AI was significantly associated with the presence of the metabolic syndrome (OR 5.1, p <0.0001). In conclusion, the apo-B/apo-AI ratio is strongly associated with the presence of individual metabolic syndrome components, with the metabolic syndrome itself, and with insulin resistance. An elevated apo-B/apo-AI ratio may constitute an important feature of the metabolic syndrome and may provide an additional mechanism to explain the increased cardiovascular risk in subjects with this syndrome.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17134631     DOI: 10.1016/j.amjcard.2006.06.029

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  28 in total

1.  Utility of ApoB/ApoA1 ratio for the prediction of cardiovascular risk in children with metabolic syndrome.

Authors:  S Savas Erdeve; E Simsek; Yildiz Dallar; Zeynep Biyikli
Journal:  Indian J Pediatr       Date:  2010-10-06       Impact factor: 1.967

2.  Atherogenic dyslipidemia and cardiovascular risk in children with nonalcoholic fatty liver disease.

Authors:  Naim Alkhouri; Christine Carter-Kent; Michael Elias; Ariel E Feldstein
Journal:  Clin Lipidol       Date:  2011-06-01

3.  Increased T cell immunoglobulin and mucin domain 3 positively correlate with systemic IL-17 and TNF-α level in the acute phase of ischemic stroke.

Authors:  Di Zhao; Nan Hou; Min Cui; Ying Liu; Xiaohong Liang; Xuewei Zhuang; Yuanyuan Zhang; Lining Zhang; Deling Yin; Lifen Gao; Yun Zhang; Chunhong Ma
Journal:  J Clin Immunol       Date:  2011-04-26       Impact factor: 8.317

4.  Disease risk factors identified through shared genetic architecture and electronic medical records.

Authors:  Li Li; David J Ruau; Chirag J Patel; Susan C Weber; Rong Chen; Nicholas P Tatonetti; Joel T Dudley; Atul J Butte
Journal:  Sci Transl Med       Date:  2014-04-30       Impact factor: 17.956

5.  The ApoB/ApoA1 ratio is associated with metabolic syndrome and its components in a Chinese population.

Authors:  Li Zhong; Qifu Li; Yuanjuan Jiang; Dan Cheng; Zhoujun Liu; Bangqiong Wang; Rong Luo; Qingfeng Cheng; Hua Qing
Journal:  Inflammation       Date:  2010-12       Impact factor: 4.092

6.  Concentration of apolipoprotein B is comparable with the apolipoprotein B/apolipoprotein A-I ratio and better than routine clinical lipid measurements in predicting coronary heart disease mortality: findings from a multi-ethnic US population.

Authors:  Justo Sierra-Johnson; Rachel M Fisher; Abel Romero-Corral; Virend K Somers; Francisco Lopez-Jimenez; John Ohrvik; Göran Walldius; Mai-Lis Hellenius; Anders Hamsten
Journal:  Eur Heart J       Date:  2008-08-01       Impact factor: 29.983

7.  Normal weight obesity: a risk factor for cardiometabolic dysregulation and cardiovascular mortality.

Authors:  Abel Romero-Corral; Virend K Somers; Justo Sierra-Johnson; Yoel Korenfeld; Simona Boarin; Josef Korinek; Michael D Jensen; Gianfranco Parati; Francisco Lopez-Jimenez
Journal:  Eur Heart J       Date:  2009-11-20       Impact factor: 29.983

8.  Dyslipidemia and cardiovascular risk: the importance of early prevention.

Authors:  M Miller
Journal:  QJM       Date:  2009-06-04

9.  Apolipoproteins A-I, B, and C-III in young adult Cherokee with metabolic syndrome with or without type 2 diabetes.

Authors:  Wenyu Wang; Sohail Khan; Piers Blackett; Petar Alaupovic; Elisa Lee
Journal:  J Clin Lipidol       Date:  2012-07-02       Impact factor: 4.766

10.  Usefulness of apolipoprotein B/apolipoprotein A-I ratio to predict coronary artery disease independent of the metabolic syndrome in African Americans.

Authors:  Byambaa Enkhmaa; Erdembileg Anuurad; Zhiyuan Zhang; Thomas A Pearson; Lars Berglund
Journal:  Am J Cardiol       Date:  2010-11-01       Impact factor: 2.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.